Physician profile
Jesse Phelps
NPI 1801670815
$1,113.70
in general payments reported to CMS, 2019-2025
12 companies · $812 in 2025
The $812 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.71 · 2024: $259 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $180.18 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.52 | 2024-2025 | Caplyta |
| Alkermes, INC. | $159.69 | 2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $154.31 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $117.76 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $96.97 | 2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $86.82 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $55.64 | 2025 | Uzedy |
| Abbvie INC. | $34.20 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $28.17 | 2023 | Livalo, Seglentis |
| Antares Pharma, INC. | $14.84 | 2024 | Xyosted |
| Astrazeneca Pharmaceuticals LP | $14.60 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.